US2005163715A1PendingUtilityA1

Dynamic organ function monitoring agents

Assignee: MALLINCKRODT INCPriority: Oct 13, 2000Filed: Mar 17, 2005Published: Jul 28, 2005
Est. expiryOct 13, 2020(expired)· nominal 20-yr term from priority
C07D 209/12C07D 209/08C07D 209/60C07D 405/14
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume in vivo.

Claims

exact text as granted — not AI-modified
1 . A method for performing a diagnostic or therapeutic procedure comprising administering to a mammal an effective amount of the formula  
       
         
           
           
               
               
           
         
       
       wherein R 16 , R 17 , R 18 , R 20 , R 21 , R 22  and R 23 , Y 3 , and Z 3  are independently selected from the group consisting of —H, C1-C10 alkoxyl, C1-C10 polyalkoxyalkyl, C1-C20 polyhydroxyalkyl, C5-C20 polyhydroxyaryl, saccharides, amino, C1-C10 aminoalkyl, cyano, nitro, halogen, hydrophilic peptides, arylpolysulfonates, C1-C10 alkyl, C5-C20 aryl, —SO 3 T, —CO 2 T, —OH, —(CH 2 ) a SO 3 T, —(CH 2 ) a OSO 3 T, —(CH 2 ) a NHSO 3 T, —(CH 2 ) a CO 2 (CH 2 ) b SO 3 T, —(CH 2 ) a OCO(CH 2 ) b SO 3 T, —(CH 2 ) a CONH(CH 2 ) b SO 3 T, —(CH 2 ) a NHCO(CH 2 ) b SO 3 T, —(CH 2 ) a NHCONH(CH 2 ) b SO 3 T, —(CH 2 ) a NHCSNH(CH 2 ) b SO 3 T, —(CH 2 ) a OCONH(CH 2 ) b SO 3 T, —(CH 2 ) a PO 3 HT, —(CH 2 ) a PO 3 T 2 , —(CH 2 ) a OPO 3 HT, —(CH 2 ) a OPO 3 T 2 , —(CH 2 ) a NHPO 3 HT, —(CH 2 ) a NHPO 3 T 2 , —(CH 2 ) a CO 2 (CH 2 ) b PO 3 HT, —(CH 2 ) a CO 2 (CH 2 ) b PO 3 T 2 , —(CH 2 ) a OCO(CH 2 ) b PO 3 HT, —(CH 2 ) a OCO(CH 2 ) b PO 3 T 2 , —(CH 2 ) a CONH(CH 2 ) b PO 3 HT, —(CH 2 ) a CONH(CH 2 ) b PO 3 T 2 , —(CH 2 ) a NHCO(CH 2 ) b PO 3 HT, —(CH 2 ) a NHCO(CH 2 ) b PO 3 T 2 , —(CH 2 ) a NHCONH(CH 2 ) b PO 3 HT, —(CH 2 ) a NHCONH(CH 2 ) b PO 3 T 2 , —(CH 2 ) a NHCSNH(CH 2 ) b PO 3 HT, —(CH 2 ) a NHCSNH(CH 2 ) b PO 3 T 2 , —(CH 2 ) a OCONH(CH 2 ) b PO 3 HT, and —(CH 2 ) a OCONH(CH 2 ) b PO 3 T 2 , —CH 2 (CH 2 —O—CH 2 ) c —CH 2 —OH, —(CH 2 ) d —CO 2 T, —CH 2 —(CH 2 —O—CH 2 ) e —CH 2 —CO 2 T, —(CH 2 ) f NH 2 , —CH 2 —(CH 2 —O—CH 2 ) g —CH 2 —NH 2 , —(CH 2 ) h —N(R a )—(CH 2 ) i —CO 2 T, and —(CH 2 ) j —N(R b )—CH 2 —(CH 2 —O—CH 2 ) k —CH 2 —CO 2 T; R 15  is selected from the group consisting of —(CH 2 ) a SO 3 T, —(CH 2 ) a OSO 3 T, —(CH 2 ) a NHSO 3 T, —(CH 2 ) a CO 2 (CH 2 ) b SO 3 T, —(CH 2 ) a OCO(CH 2 ) b SO 3 T, —(CH 2 ) a CONH(CH 2 ) b SO 3 T, —(CH 2 ) a NHCO(CH 2 ) b SO 3 T, —(CH 2 ) a NHCONH(CH 2 ) b SO 3 T, —(CH 2 ) a NHCSNH(CH 2 ) b SO 3 T, and —(CH 2 ) a OCONH(CH 2 ) b SO 3 T; R 19  is selected from the group consisting of —H, C5-C10 alkoxyl, C5-C10 polyalkoxyalkyl, C7-C20 polyhydroxyalkyl, C5-C20 polyhydroxyaryl, saccharides, amino, C1-C10 aminoalkyl, cyano, nitro, halogen, hydrophilic peptides, arylpolysulfonates, C7-C10 alkyl, C5-C20 aryl, —SO 3 T, —CO 2 T, —OH, —(CH 2 ) a SO 3 T, —(CH 2 ) a OSO 3 T, —(CH 2 ) a NHSO 3 T, —(CH 2 ) a CO 2 (CH 2 ) b SO 3 T, —(CH 2 ) a OCO(CH 2 ) b SO 3 T, —(CH 2 ) a CONH(CH 2 ) b SO 3 T, —(CH 2 ) a NHCO(CH 2 ) b SO 3 T, —(CH 2 ) a NHCONH(CH 2 ) b SO 3 T, —(CH 2 ) a NHCSNH(CH 2 ) b SO 3 T, —(CH 2 ) a OCONH(CH 2 ) b SO 3 T, —(CH 2 ) a PO 3 HT, —(CH 2 ) a PO 3 T 2 , —(CH 2 ) a OPO 3 HT, —(CH 2 ) a OPO 3 T 2 , —(CH 2 ) a NHPO 3 HT, —(CH 2 ) a NHPO 3 T 2 , —(CH 2 ) a CO 2 (CH 2 ) b PO 3 HT, —(CH 2 ) a CO 2 (CH 2 ) b PO 3 T 2 , —(CH 2 ) a OCO(CH 2 ) b PO 3 HT, —(CH 2 ) a OCO(CH 2 ) b PO 3 T 2 , —(CH 2 ) a CONH(CH 2 ) b PO 3 HT, —(CH 2 ) a CONH(CH 2 ) b PO 3 T 2 , —(CH 2 ) a NHCO(CH 2 ) b PO 3 HT, —(CH 2 ) a NHCO(CH 2 ) b PO 3 T 2 , —(CH 2 ) a NHCONH(CH 2 ) b PO 3 HT, —(CH 2 ) a NHCONH(CH 2 ) b PO 3 T 2 , —(CH 2 ) a NHCSNH(CH 2 ) b PO 3 HT, —(CH 2 ) a NHCSNH(CH 2 ) b PO 3 T 2 , —(CH 2 ) a OCONH(CH 2 ) b PO 3 HT, and —(CH 2 ) a OCONH(CH 2 ) b PO 3 T 2 , —CH 2 (CH 2 —O—CH 2 ) c —CH 2 —OH, —(CH 2 ) d —CO 2 T, —CH 2 —(CH 2 —O—CH 2 ) e —CH 2 —CO 2 T, —(CH 2 ) f —NH 2 , —CH 2 —(CH 2 —O—CH 2 ) g —CH 2 —NH 2 , —(CH 2 ) h —N(R a )—(CH 2 ) l —CO 2 T, and —(CH 2 ) j —N(R b )—CH 2 —(CH 2 —O—CH 2 ) k —CH 2 —CO 2 T; W 3  and X 3  are selected from the group consisting of —CR c R d , —O—, —NR c , —S—, and —Se; V 3  is a single bond or is selected from the group consisting of —O—, —S—, —Se—, and —NR a ; a, b, d, f, h, i, and j independently vary from 1-10; c, e, g, and k independently vary from 1-100; a 3  and b 3  vary from 0 to 5; R a , R b , R c , and R d  are defined in the same manner as Y 3 ; and T is either H or a negative charge.  
     
     
         2 . The method of  claim 1  comprising administering an effective amount of the formula wherein R 16 , R 17 , R 18 , R 20 , R 21 , R 22  and R 23 , Y 3 , and Z 3  are independently selected from the group consisting of —H, C1-C5 alkoxyl, C1-C5 polyalkoxyalkyl, C1-C10 polyhydroxyalkyl, C5-C20 polyhydroxyaryl, mono- and disaccharides, nitro, hydrophilic peptides, arylpolysulfonates, C1-C5 alkyl, C5-C20 aryl, —SO 3 T, —CO 2 T, —OH, —(CH 2 ) a SO 3 T, —(CH 2 ) a OSO 3 T, —(CH 2 ) a NHSO 3 T, —(CH 2 ) a CO 2 (CH 2 ) b SO 3 T, —(CH 2 ) a OCO(CH 2 ) b SO 3 T, —CH 2 (CH 2 —O—CH 2 ) c —CH 2 —OH, —(CH 2 ) d —CO 2 T, —CH 2 —(CH 2 —O—CH 2 ) e —CH 2 —CO 2 T, —(CH 2 ) f —NH 2 , —CH 2 —(CH 2 —O—CH 2 ) g —CH 2 —NH 2 , —(CH 2 ) h —N(R a )—(CH 2 ) i —CO 2 T, and —(CH 2 ) j —N(R b )—CH 2 —(CH 2 —O—CH 2 ) k —CH 2 —CO 2 T; R 15  is selected from the group consisting of —(CH 2 ) a SO 3 T, —(CH 2 ) a OSO 3 T, —(CH 2 ) a NHSO 3 T, —(CH 2 ) a CO 2 (CH 2 ) b SO 3 T, and —(CH 2 ) a OCO(CH 2 ) b SO 3 T; R 19  is selected from the group consisting of —H, C5 alkoxyl, C5 polyalkoxyalkyl, C7-C10 polyhydroxyalkyl, C5-C20 polyhydroxyaryl, mono- and disaccharides, nitro, hydrophilic peptides, arylpolysulfonates, C5-C20 aryl, —SO 3 T, —CO 2 T, —OH, —(CH 2 ) a SO 3 T, —(CH 2 ) a OSO 3 T, —(CH 2 ) a NHSO 3 T, —(CH 2 ) a CO 2 (CH 2 ) b SO 3 T, —(CH 2 ) a OCO(CH 2 ) b SO 3 T, —CH 2 —(CH 2 —O—CH 2 ) c —CH 2 —OH, —(CH 2 ) d —CO 2 T, —CH 2 —(CH 2 —O—CH 2 ) e —CH 2 —CO 2 T, —(CH 2 ) f —NH 2 , —CH 2 —(CH 2 —O—CH 2 ) g —CH 2 —NH 2 , —(CH 2 ) h —N(R a )—(CH 2 ) l —CO 2 T, and —(CH 2 ) l —N(R b )—CH 2 —(CH 2 —O—CH 2 ) k —CH 2 —CO 2 T; W 3  and X 3  are selected from the group consisting of —CR c R d , —O—, —NR c , —S—, and —Se; V 3  is a single bond or is selected from the group consisting of —O—, —S—, —Se—, and —NR a ; a, b, d, f, h, i, and j independently vary from 1-5; c, e, g, and k independently vary from 1-50; each a 3  and b 3  independently vary from 0 to 5; R a , R b , R c , and R d  are defined in the same manner as Y 3 ; and T is either H or a negative charge.  
     
     
         3 . The method of  claim 1  wherein said procedure utilizes light of wavelength in the region of 350-1300 nm.  
     
     
         4 . The method of  claim 1  wherein said procedure comprises monitoring a blood clearance profile by fluorescence using light of wavelength in the region of 350 to 1300 nm.  
     
     
         5 . The method of  claim 1  wherein said procedure comprises monitoring a blood clearance profile by absorption using light of wavelength in the region of 350 to 1300 nm.  
     
     
         6 . The method of  claim 1  wherein said procedure is for physiological function monitoring.  
     
     
         7 . The method of  claim 6  wherein said procedure is for renal function monitoring.  
     
     
         8 . The method of  claim 6  wherein said procedure is for cardiac function monitoring.  
     
     
         9 . The method of  claim 6  wherein said procedure is for kidney function monitoring.  
     
     
         10 . The method of  claim 6  wherein said procedure is for determining organ perfusion in vivo.

Join the waitlist — get patent alerts

Track US2005163715A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.